Thematische Bibliographien / Oxaliplatin

Inhaltsverzeichnis

  1. Zeitschriftenartikel
  2. Dissertationen
  3. Bücher
  4. Buchteile
  5. Konferenzberichte
  6. Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Oxaliplatin“

Autor: Grafiati
Veröffentlicht am 4. Juni 2021
Zuletzt aktualisiert am 25. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Oxaliplatin" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Oxaliplatin"

1

Ye, Tong, Chen Wu, Jintong Na, Xiyu Liu, and Yong Huang. "Multi-Pathway Study for Oxaliplatin Resistance Reduction." Current Issues in Molecular Biology 47, no. 3 (2025): 172. https://doi.org/10.3390/cimb47030172.

Der volle Inhalt der Quelle
Annotation:
Chemotherapy for cancer frequently uses platinum-based medications, including oxaliplatin, carboplatin, and cisplatin; however, due to their high systemic toxicity, lack of selectivity, drug resistance, and other side effects, platinum-based medications have very limited clinical application. As a first-line medication in antitumor therapy, oxaliplatin must be administered to minimize side effects while achieving anticancer objectives. A new CDC7 inhibitor called XL413 has demonstrated promising antitumor therapeutic effects in a variety of malignant tumors and may have anticancer properties.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Ain, Noor ul, Nusrat Bano, Anwar Ejaz Beg, Kamran Hameed, Talha Bin Fayyaz, and Rafia Sadaf. "HEMATOLOGICAL TOXICITY IN RATS;." Professional Medical Journal 24, no. 02 (2017): 342–46. http://dx.doi.org/10.29309/tpmj/2017.24.02.525.

Der volle Inhalt der Quelle
Annotation:
Objectives: Oxaliplatin causes hematological toxicities in clinical setting whichlimits its efficacy. The aim of this study is to investigate the therapeutic effects of Andrographispaniculata against hematological toxicity caused by oxaliplatin. Study design: Experimentalanimal study. Period: Study takes 8 month from March 2015 to Oct 2015. Setting: Dow universityanimal house. Method: Wistar albino male rats, divided into 3 equals groups (n=6): GroupN* was a control group (0.9% normal saline), Group NP0 was Oxaliplatin treated group andGroup NP1 was prophylactically treated with Andrographis p
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Grothey, A., D. A. Nikcevich, J. A. Sloan, et al. "Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial." Journal of Clinical Oncology 27, no. 15_suppl (2009): 4025. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4025.

Der volle Inhalt der Quelle
Annotation:
4025 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant setting. We recently demonstrated the protective effect of CaMg against oxaliplatin-induced sNT as assessed by NCI-CTC (Nikcevich ASCO 2008). It is unclear, though, if CaMg reduced acute and/or chronic, cumulative sNT. Methods: 104 pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to IV CaMg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo (PL) in a
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Pires, Lívia Márcia Vidal, and Patrícia Dos Santos Claro Fuly. "Mapeamento de fatores clínicos preditivos da neuropatia sensorial periférica induzida por oxaliplatina: revisão sistemática." Revista Recien - Revista Científica de Enfermagem 11, no. 35 (2021): 382–97. http://dx.doi.org/10.24276/rrecien2021.11.35.382-397.

Der volle Inhalt der Quelle
Annotation:
O objetivo deste estudo foi realizar um mapeamento dos fatores clínicos preditivos da Neuropatia Sensorial Periférica induzida pela Oxaliplatina. Para tanto, foi realizada uma revisão sistemática, elaborada a partir das recomendações da diretriz PRISMA. A estratégia PICO também foi utilizada para formular a questão de pesquisa e orientar a busca nas bases de dados: PubMed, Embase, Scopus, BVS/IBECS e CINAHL. Foram selecionadas 26 publicações para análise final e inclusão na revisão. As publicações foram classificadas quanto ao nível de evidência e grau de recomendação, de acordo com o sistema
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Cho, Soohee, Kristen Miller, Jacqueline Rowley, et al. "OTHR-03. Oxaliplatin as a hearing-sparing alternative to carboplatin in tandem autologous stem cell transplants in pediatric CNS malignancy." Neuro-Oncology 24, Supplement_1 (2022): i147. http://dx.doi.org/10.1093/neuonc/noac079.542.

Der volle Inhalt der Quelle
Annotation:
Abstract BACKGROUND: Intensive chemotherapy with tandem autologous stem cell transplants (autoSCT) is shown to improve survival for children with CNS malignancy. Platinum-based chemotherapeutic agents in these regimens, mainly cisplatin and carboplatin, have resulted in significant sensorineural hearing loss. Oxaliplatin, a newer platinum-based agent, is considered less ototoxic. Empiric substitution of oxaliplatin for carboplatin in preparative regimens for autoSCT have been tried. However, the survival and ototoxicity outcomes have not been studied. OBJECTIVE: To compare the overall survival
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Connors, Jeremy S., Linda Zhang, Koji Sasaki, et al. "Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms." Blood 142, Supplement 1 (2023): 4220. http://dx.doi.org/10.1182/blood-2023-190672.

Der volle Inhalt der Quelle
Annotation:
Introduction As a DNA-damaging agent, platinum-based chemotherapy serves as a cornerstone in cancer treatment. However, its widespread use has been associated with increased incidence of therapy-related myeloid neoplasms (t-MNs). Among the three most commonly used platinum chemotherapies - cisplatin, carboplatin, and oxaliplain - oxaliplatin presents a distinctive clinical usage and toxicity profile. Predominantly utilized in treating gastrointestinal tract (GI) cancers, oxaliplatin manifests a distinct toxicity pattern when compared to its counterparts. This variance is supported by a previou
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Lipp and Hartmann. "Platinverbindungen: Metabolismus, Toxizität und supportive Strategien." Praxis 94, no. 6 (2005): 187–98. http://dx.doi.org/10.1024/0369-8394.94.6.187.

Der volle Inhalt der Quelle
Annotation:
Mit Oxaliplatin wurde der erste Vertreter der DACH-Platin-Verbindungen in die Klinik eingeführt (DACH: Diaminocyclohexan), der bei guter Verträglichkeit die höchste Aktivität zur Behandlung des fortgeschrittenen kolorektalen Karzinoms aufweist. Aufgrund der hohen, gegenüber Cisplatin besseren in vitro-Aktivität des Oxaliplatins auch gegenüber anderen Tumorentitäten sind die klinischen Studien mit Oxaliplatin in den letzten Jahren erheblich ausgeweitet worden. Der breite Einsatz der genannten Platinverbindungen darf allerdings nicht darüber hinwegtäuschen, dass diese Wirkstoffe über beachtliche
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1378 (2011): 27. http://dx.doi.org/10.2165/00128415-201113780-00098.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1384 (2012): 43. http://dx.doi.org/10.2165/00128415-201213840-00174.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1385 (2012): 35. http://dx.doi.org/10.2165/00128415-201213850-00129.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Dissertationen zum Thema "Oxaliplatin"

1

Xiaoqing, Liu. "Dose-banding studies on oxaliplatin." Thesis, University of Plymouth, 2016. http://hdl.handle.net/10026.1/8081.

Der volle Inhalt der Quelle
Annotation:
Oxaliplatin is an anticancer drug widely used in cancer chemotherapy. This thesis evaluates whether a specific dose-banding scheme for oxaliplatin could replace the individual dosing method that is currently used in the oxaliplatin administration. Dose-banding was introduced into UK clinical practice in 2001, as it reduces delays in patients receiving their treatment and, through quality control and end-product testing, safeguards the infusion quality and patient safety. A range of studies were included in this thesis: an extended stability study on oxaliplatin infusions using a sequential tem
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Vincent, Jacob Adam. "Sensorimotor Deficits Following Oxaliplatin Chemotherapy." Wright State University / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=wright1496136263522854.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Wieczerzak, Krystyna Blanka. "Sensorimotor Analysis of Oxaliplatin Treated Rats." Wright State University / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=wright1432856752.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Robinson, Stuart Michael. "The pathogenesis of oxaliplatin induced sinusoidal obstruction syndrome." Thesis, University of Newcastle upon Tyne, 2013. http://hdl.handle.net/10443/1942.

Der volle Inhalt der Quelle
Annotation:
Oxaliplatin based chemotherapy has demonstrated remarkable efficacy in down staging colorectal liver metastases such that patients initially considered to have inoperable disease are able to undergo a potentially curative resection. In addition the use of neoadjuvant Oxaliplatin based chemotherapy has been shown to improve progression free survival following liver resection. Taken together this means that ever increasing numbers of patients are presenting for liver resection having received multiple cycles of chemotherapy. Whilst this approach has many advantages the use of pre-operative chemo
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

MONZA, LAURA. "In vitro models for studying oxaliplatin neurotoxic effects." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2019. http://hdl.handle.net/10281/241333.

Der volle Inhalt der Quelle
Annotation:
L’oxaliplatino (OHP) è un composto del platino di terza generazione, usato in combinazione con 5-fluorouracile e leucovorin per il trattamento del tumore al colon-retto metastatico. L’assunzione di OHP è in grado di indurre l’insorgenza di due fenomeni di tossicità, acuto e cronico. La tossicità acuta è caratterizzata da disestesie e parestesie transitorie esacerbate dal contatto col freddo. La gravità di questi sintomi è predittiva per lo sviluppo della neuropatia sensoriale cronica. Sebbene i meccanismi patogenetici alla base della tossicità acuta non siano stati del tutto chiariti, l’ipote
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Cerles, Olivier. "Prévention des neuropathies périphériques induites par les chimiothérapies par une modulation pharmacologique des dérives des formes réactives de l'oxygène et des récepteurs muscariniques." Thesis, Sorbonne Paris Cité, 2017. http://www.theses.fr/2017USPCB106.

Der volle Inhalt der Quelle
Annotation:
Les chimiothérapies à base de sels de platine exercent leurs effets anti-tumoraux en compromettant l'intégrité de l'ADN. Cette cytotoxicité conduit à une augmentation du stress oxydant qui, à son tour, favorise les processus de mort cellulaire. L'oxaliplatine indiquée dans les cancers métastatiques secondaires du colon et dans les cancers colorectaux, induit une augmentation des espèces réactives de l’oxygène en diminuant le glutathion réduit dans les cellules cancéreuses. Similairement aux autres chimiothérapies à base de sels de platine, elle doit être utilisée avec précaution. En effet, la
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Azarm, Asieh. "Effect of oxaliplatin on HCT116 P53+/- colon cancer cells." Thesis, Högskolan i Skövde, Institutionen för vård och natur, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-5451.

Der volle Inhalt der Quelle
Annotation:
Oxaliplatin as an effective chemotherapeutic agent in FOLFOX regimens is using to treat colorectal cancer. In this study we investigate cytotoxicity of Oxaliplatin as single chemotherapeutic agent toHCT116P53+/- to identify molecular mechanism of Oxaliplatin action in induction of apoptosis pathway. Oxaliplatin exposure to HCT116P53+/- colorectal cell lines with deficiency of mismatch repair characteristic resulted to decrease the number of viable cells through apoptosis. Effective Oxaliplatin concentrations (IC50) which inhibit 50% of cell viability were determined using XTT method. Standard
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Golf, Alexander. "Eine randomisierte Phase-II-Studie mit Capecitabin/Oxaliplatin versus Gemcitabin/Capecitabin versus Gemcitabin/Oxaliplatin bei Patienten mit lokal fortgeschrittenem inoperablem oder metastasiertem Pankreaskarzinom." Diss., lmu, 2009. http://nbn-resolving.de/urn:nbn:de:bvb:19-108951.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

POZZI, ELEONORA. "OXALIPLATIN-INDUCED PERIPHERAL NEUROTOXICITY IN MOUSE MODELS: DIFFERENT TREATMENT SCHEDULES AND FOCUS ON OXIDATIVE STRESS." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2020. http://hdl.handle.net/10281/261949.

Der volle Inhalt der Quelle
Annotation:
La tossicità dei farmaci antitumorali rappresenta una delle principali limitazioni nella pratica clinica. Tra gli effetti collaterali dei farmaci chemioterapici, la neurotossicità periferica è uno dei più invalidanti per i pazienti malati di cancro. Oxaliplatino (OHP), un composto ampiamente usato per il trattamento del carcinoma del colon-retto metastatico, è uno dei farmaci antineoplastici più neurotossici. I pazienti possono sviluppare due forme clinicamente distinte di neuropatia periferica: una forma acuta aggravata dal freddo ed una neuropatia sensoriale distale cronica. A causa della m
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Gong, Peng Chaney Stephen G. "Modeling conformational dynamics of cisplatin and oxaliplatin adducts with DNA." Chapel Hill, N.C. : University of North Carolina at Chapel Hill, 2006. http://dc.lib.unc.edu/u?/etd,496.

Der volle Inhalt der Quelle
Annotation:
Thesis (M.S.)--University of North Carolina at Chapel Hill, 2006.<br>Title from electronic title page (viewed Oct. 10, 2007). "... in partial fulfillment of the requirements for the degree of Master of Science in the Department of Biomedical Engineering." Discipline: Biomedical Engineering; Department/School: Medicine.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Bücher zum Thema "Oxaliplatin"

1

National Institute for Clinical Excellence. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. NICE, 2002.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

M, Lloyd Jones, and National Co-ordinating Centre for HTA (Great Britain), eds. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Core Research on behalf of NCCHTA, 2001.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Lloyd, Jones M., National Co-ordinating Centre for HTA (Great Britain), and Health Technology Assessment Programme, eds. A Rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. NCCHTA, 2001.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

R, Kelland Lloyd, and Farrell Nicholas 1948-, eds. Platinum-based drugs in cancer therapy. Humana Press, 2000.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Schmoll, H. J. Eloxatin (Oxaliplatin. S Karger Pub, 2003.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Marshall, John L. The Clinical Use of Oxaliplatin: Case Studies and Roundtable Discussion, Including a Clinical Discussion on Audio CD. Cmp United Business Media, 2004.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Schmoll, H. J. Oxaliplatin (eloxatin): Fortschritte In Der Tumortherapie 2004 (Onkologie). S Karger Pub, 2004.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Schmoll, H. J. Oxaliplatin (Eloxatin): Fortschritte in Der Tumortherapie (Onkologie). S Karger Pub, 2000.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

McLeon, Kelly. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. Edited by SreyRam Kuy and Miguel A. Burch. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199384075.003.0011.

Der volle Inhalt der Quelle
Annotation:
The landmark MOSAIC trial examined whether the addition of oxaliplatin to a postoperative adjuvant treatment regimen of fluorouracil and leucovorin affected disease-free survival from colon cancer. The MOSAIC trial established the efficacy of FOLFOX over 5-FU/LV as adjuvant treatment for stage III colon cancer and established FOLFOX4 as the reference standard for adjuvant treatment for stage III disease. This chapter describes the basics of the study, including funding, year study began, year study was published, study location, who was studied, who was excluded, how many patients, study desig
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Publications, ICON Health. Oxaliplatin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Buchteile zum Thema "Oxaliplatin"

1

Mader, Ines, Patrizia Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, and Sabine M. Wassertheurer. "Oxaliplatin." In Paravasation von Zytostatika. Springer Vienna, 2002. http://dx.doi.org/10.1007/978-3-7091-3799-4_40.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Mader, Ines, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz, and Sabine Wassertheurer. "Oxaliplatin." In Extravasation of Cytotoxic Agents. Springer Vienna, 2010. http://dx.doi.org/10.1007/978-3-211-88893-3_47.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Mader, Ines, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, and Sabine M. Wassertheurer. "Oxaliplatin." In Extravasation of Cytotoxic Agents. Springer Vienna, 2003. http://dx.doi.org/10.1007/978-3-7091-3710-9_40.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Bonetti, Andrea, and Furini Lara. "Oxaliplatin-Based Chemotherapy for Colon Cancer." In Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-459-3_31.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Stein, Alexander. "Oxaliplatin, Clinical Use in Cancer Patients." In Encyclopedia of Metalloproteins. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-1533-6_563.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Taguchi, T. "Clinical Trials of Oxaliplatin and DWA2114R." In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-0218-4_19.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Aschele, Carlo, Elisa Bennicelli, and Amalia Milano. "Should Oxaliplatin Be Added to Preoperative Chemoradiation?" In Multidisciplinary Management of Rectal Cancer. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-43217-5_35.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Jacobson, Stacy D., Steven R. Alberts, and Richard M. Goldberg. "Oxaliplatin in the Treatment of Colorectal Cancer." In Colorectal Cancer. Humana Press, 2002. http://dx.doi.org/10.1007/978-1-59259-160-2_29.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Aschele, Carlo. "Should Oxaliplatin Be Added to Preoperative Chemoradiation?" In Multidisciplinary Management of Rectal Cancer. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-25005-7_18.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Gatti, Laura, and Paola Perego. "Cellular Resistance to Oxaliplatin and Drug Accumulation Defects." In Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-459-3_16.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Oxaliplatin"

1

Farrukh, A., and W. Mickey. "Interstitial Pneumonitis From Gemcitabine and Oxaliplatin Combination." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3171.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Jungwirth, Ute, Petra Heffeter, Johannes Gojo, et al. "Abstract C93: Novel monosubstituted oxaliplatin analogs with improved characteristics." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-c93.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Kuang, Yuting, Anthony El-Khoueiry, Pietro Taverna, Mats Ljungman, and Nouri Neamati. "Abstract 2533: SGI-110 priming sensitizes hepatocellular carcinoma cells to oxaliplatin." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2533.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Chen, Yufeng, Zhaoliang Yu, Peng Deng, and Xiaojian Wu. "Abstract 972: Pharmacological targeting CDC7 sensitizes oxaliplatin treatment in colorectal cancer." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-972.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Dosualdo, Caique Alberto. "Reversible posterior encephalopathy syndrome as a rare complication of oxaliplatin chemotherapy: a case report." In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.399.

Der volle Inhalt der Quelle
Annotation:
Introduction: The reversible posterior encephalopathy syndrome corresponds to a clinical and radiological diagnosis marked by headache, altered mental status, reduced visual acuity and seizures, associated with vasogenic edema mainly in posterior white matter. It presents a large heterogeneity of etiologies, such as cytotoxic drugs, eclampsia, vasculitis, and nephropathies, with arterial hypertension being the most important. In that way, quick diagnostic investigation is necessary to provide a better prognosis. Case report: Case report of a patient who was in adjuvance combined chemotherapy,
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Wu, Xiaojun, E. Yiwen, Xinlong Xu, and Li Wang. "Interaction between DNA and Oxaliplatin in Aqueous Solution Studied Using THz-TDS." In Laser and Tera-Hertz Science and Technology. OSA, 2012. http://dx.doi.org/10.1364/ltst.2012.sf2a.3.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Fortuna, M., P. Tavcar, M. Sonc, et al. "5PSQ-056 Evaluation of oxaliplatin-specific neurotoxicity based on total cumulative dose." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.410.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

McIntyre, Alexander, Fiammetta Falcone, Patrick G. Johnston, Daniel B. Longley, and Simon S. McDade. "Abstract LB-016: Nutlin and oxaliplatin induce p53-dependent addiction to FLIP." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-lb-016.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Huang, Huakang, and Daniel W. Rosenberg. "Abstract 3608: Prostaglandin E-2 promotes resistance to oxaliplatin in colorectal cancer cells." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3608.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Sorensen, Kathleen, Jennifer Jess, Susan Goosen, et al. "Abstract 5817: Oxaliplatin and ATR inhibitors show strong synergy in Ewing sarcoma cells." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5817.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Oxaliplatin"

1

Si, Yue, Yan Yuan, Yihua Zou, Haiyan Wang, and Yong Xin. S-1 or Capecitabine in combination with Oxaliplatin for Gastric Cancer：A meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.1.0064.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Zhou, Tong, Shuo Wang, Lanxin Zhang, et al. Efficacy and Safety of Compound Kushen Injection Combined With Oxaliplatin-Based Chemotherapy in the Treatment of Advanced Colorectal Cancer: a Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.9.0059.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Jing, Hailiang, Jianing Jian, Hong Liu, et al. The effect of oral Chinese herbal medicine on Oxaliplatin-induced Peripheral Neuropathy in patients with advanced colorectal cancer treated with FOLFOX: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.12.0124.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Wang, Shuo, Xueqian Wang, Tong Zhou, et al. Efficacy of Chinese herbal injections combined with fluoropyrimidine and oxaliplatin-based chemotherapy for advanced colorectal cancer: a protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.10.0050.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Die Auswahlen zum Thema "Oxaliplatin" für konkrete Quellenarten können Sie auch interessieren:
Zeitschriftenartikel Dissertationen
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie